Developer docs
API playgroundTry for free, no card

Search company profiles

Neurotrack

Full company profile

uuid0000bgt

Namestring
Neurotrack
Legal namestring
Neurotrack Technologies, Inc.
Websiteurl
neurotrack.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Neurotrack is a Redwood City-based digital health company founded in 2012 that develops FDA-registered, cloud-based cognitive screening and brain health solutions targeting early detection of mild cognitive impairment, Alzheimer's disease, and related dementias. Its core product is a 3-minute digital cognitive screening test (Class II medical device) that uses proprietary machine-learning algorithms trained on large datasets to provide age-specific, DSM-5-aligned scoring across any device, with integration into all major electronic health record systems. The company complements the screener with a Memory Health Program — an app-based digital therapeutic combining board-certified health coaching with multi-domain lifestyle interventions (nutrition, physical activity, vascular health, sleep, stress, cognitive training) — plus a patient education library of 100+ brain-health articles. Original eye-tracking technology developed at Emory University remains in research applications only and is not part of the current clinical offering.

Neurotrack monetizes through quote-based, annual enterprise subscriptions to healthcare organizations, with three primary customer segments: (1) healthcare providers and health systems (e.g., Sutter Health serving 3.5 million patients, Providence, Stanford Medicine, Desert Oasis Healthcare) using the platform in primary care, home health, and specialty settings; (2) Medicare Advantage plans and payers using cognitive screening for population health management, Star Ratings, and HEDIS/CMS compliance; and (3) life and long-term care insurers (e.g., Nationwide, Dai-ichi Life, Hannover Re) for underwriting and policyholder screening. Go-to-market is enterprise field sales targeting large health systems and payers, with deployments measured in weeks. The company holds 11 patents on its assessment technology and reports 375+ peer-reviewed publications, 25 core studies, and SOC 2, HIPAA, and ISO 13485 certifications. Leadership is anchored by co-founder and CEO Elli Kaplan, with a Chief Growth Officer (hired May 2023), CTO, CSO, and VP-level teams in Strategic Partnerships, Marketing, and Customer Success. Total disclosed funding since 2013 is approximately $47M+ across multiple rounds including a $21M raise in 2019 (Khosla Ventures-led) and a $10M raise in November 2022, plus a $3.3M NIA SBIR grant.

Short descriptiontext

Neurotrack is a digital health company that sells an FDA-registered 3-minute cognitive screening test and a Memory Health Program to healthcare providers, Medicare Advantage plans, and long-term care insurers for early detection of Alzheimer's and related dementias.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cognitive screening software, digital health platform, dementia detection tools, clinical assessment software, healthcare screening solutions
Industry3 codes
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLALACAC
Behavioral Health & Psychiatry Virtual Care (Payer Network)
Healthcare & Life Sciences/Telehealth Platforms/Payer-Sponsored Virtual Care Platforms
NAICS code1 code
  • Residential Intellectual and Developmental Disability Facilities623210
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Digital Cognitive Health Screening
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Cognitive Assessment Licensing/SaaS
TypeSubscription Recurring
Description

Digital cognitive screening solutions licensed to healthcare organizations including health systems, providers, and payers. The company provides technology that can be administered in-clinic or remotely, with pricing likely based on volume or subscription model.

neurotrack.com
2Health Coaching Services
TypeSubscription Recurring
Description

1:1 support from board-certified health coaches integrated into the cognitive health program. Partnership with Fortune 100 long-term care insurance provider making services available to policy holders.

neurotrack.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise healthcare organizations
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for health systems and provider networks. No specific tiers or pricing publicly listed.

neurotrack.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Neurotrack develops and sells a 3-minute digital cognitive screening test (FDA-registered Class II medical device) and a Memory Health Program (digital therapeutic with 1:1 health coaching) used by healthcare providers, health systems, payers, and insurers for early detection of mild cognitive impairment and dementia. The platform integrates with all major EHR systems and supports Annual Wellness Visit compliance and population-wide cognitive screening.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90% of staff say Neurotrack's screener is easy to use
+4 more records
Product overview1 text field

Neurotrack offers a unified cognitive health platform centered on a 3-minute digital cognitive screening test for clinical detection of mild cognitive impairment and dementia, paired with a Memory Health Program that delivers multi-domain lifestyle interventions and 1:1 health coaching. A patient education library of 100+ articles supports behavior change across modifiable risk factors. The company's original eye-tracking technology, developed by co-founders at Emory University, is now reserved for research applications. All clinical products are FDA-registered, work on any device, integrate with EHR systems, and are SOC 2 and HIPAA compliant.

Product and service2 records
1Neurotrack 3-Minute Cognitive Screening Test
CategoryDigital cognitive screening software
Description

A rapid digital cognitive screening tool that delivers objective, DSM-5-aligned cognitive baseline assessment in approximately 3 minutes for healthcare providers and payers in primary care and Annual Wellness Visit settings. FDA-registered Class II medical device that integrates with all major EHR systems and works on any device.

2Neurotrack Memory Health Program
CategoryDigital therapeutic / cognitive health program
Description

An app-based digital therapeutic providing multi-domain lifestyle interventions and 1:1 health coaching to address modifiable Alzheimer's risk factors including physical activity, nutrition, vascular health, sleep, stress, social engagement, and cognitive training. Includes multi-modal neuropsychological assessments for baseline and longitudinal cognitive health measurement; intended for individuals at risk for cognitive decline and their healthcare providers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Sutter Health, serving 3.5 million patients and consistently ranked among top U.S. health systems, is using Neurotrack's cognitive screening for innovative new workflows. This is a flagship partnership demonstrating deployment at a major health system level.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Fortune 100 provider of long-term care insurance partnered to make Neurotrack's cognitive assessment and health coaching services available to 30,000+ policy holders. Three-minute online cognitive screening for underwriting.

3Dai-ichi Life
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

Partnership with Japan's second largest life insurance company to sell a dementia insurance product allowing members to take Neurotrack's five-minute Imprint Memory Assessment test via eye-tracking program. Early deployment December 2018.

neurotrack.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Desert Oasis Healthcare, a California healthcare provider, implemented Neurotrack's screening program that's closing gaps and connecting patients to care. Features testimonial from Brian Hodgkins, PharmD, EVP of Clinical Operations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Dr. Michelle Gray at the University of Arkansas Exercise Science Research Center for NIA-funded study on health education and coaching reducing Alzheimer's risk factors. Study published in GeroScience.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Major reinsurance company partner shown in commercial and research partners section of website.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major health system partner using Neurotrack's cognitive screening solutions, shown in commercial and research partners section.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Non-profit foundation partner shown in commercial and research partners section, focused on accelerating Alzheimer's therapeutics development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic medical center partner shown in commercial and research partners section.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Linus Health is a Boston-based digital health company offering digital cognitive assessments (e.g., DCTclock, Linus Screening) to health systems and payers — the same primary care and MA customer base Neurotrack serves, with overlapping FDA-cleared digital cognitive screening products.

TypeDirect peer
Description

Cognivue makes FDA-cleared computerized cognitive assessment devices used in primary care and specialty clinics, overlapping directly with Neurotrack's FDA-registered Class II cognitive screener and the same provider buyer persona.

TypeBroad incumbent
Description

Biogen markets Leqembi, an early-stage Alzheimer's therapeutic whose uptake directly increases demand for early cognitive screening — making it an adjacent incumbent whose commercial priorities shape the market Neurotrack serves.

TypeBroad incumbent
Description

Quest Diagnostics is a large clinical laboratory network now offering AD-Detect blood-based Alzheimer's tests; as a broad incumbent it competes with Neurotrack at the 'how to detect cognitive decline' clinical workflow level for primary care and payer customers.

TypeBroad incumbent
Description

Signant Health is a large clinical-trial technology provider that historically used Neurotrack-style cognitive assessments (and competes with similar offerings) for CNS trials, representing a broader incumbent in the cognitive assessment ecosystem.

TypeDirect peer
Description

Creyos offers online cognitive assessments and a digital health platform sold to providers, payers, and researchers, competing for the same primary care cognitive screening workflow and population-health use cases as Neurotrack.

TypeEmerging player
Description

Altoida develops FDA-cleared digital cognitive assessments using augmented reality and digital biomarkers, with a similar aim of detecting early signs of cognitive decline. It is a more research-stage but directly comparable peer in digital cognitive screening.

TypeDirect peer
Description

BrainCheck provides digital cognitive assessment and care coordination tools used by primary care providers and neurologists. It directly competes with Neurotrack's 3-minute cognitive screener in the same clinical workflow and reimbursement context.

TypeEmerging player
Description

C2N Diagnostics provides blood-based biomarker tests (e.g., PrecivityAD) for Alzheimer's detection, representing a complementary rather than overlapping modality that competes for the same 'early Alzheimer's detection' clinical decision point as Neurotrack's screener.

TypeEmerging player
Description

Savonix offers a digital neurocognitive assessment platform delivered via mobile devices, targeting similar healthcare, payer, and population-health customers as Neurotrack for cognitive screening and brain health monitoring.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurotrack

Digital Cognitive Health Screeningneurotrack.com

Neurotrack is a digital health company that sells an FDA-registered 3-minute cognitive screening test and a Memory Health Program to healthcare providers, Medicare Advantage plans, and long-term care insurers for early detection of Alzheimer's and related dementias.

What Neurotrack does

Neurotrack is a Redwood City-based digital health company founded in 2012 that develops FDA-registered, cloud-based cognitive screening and brain health solutions targeting early detection of mild cognitive impairment, Alzheimer's disease, and related dementias. Its core product is a 3-minute digital cognitive screening test (Class II medical device) that uses proprietary machine-learning algorithms trained on large datasets to provide age-specific, DSM-5-aligned scoring across any device, with integration into all major electronic health record systems. The company complements the screener with a Memory Health Program — an app-based digital therapeutic combining board-certified health coaching with multi-domain lifestyle interventions (nutrition, physical activity, vascular health, sleep, stress, cognitive training) — plus a patient education library of 100+ brain-health articles. Original eye-tracking technology developed at Emory University remains in research applications only and is not part of the current clinical offering.

Neurotrack monetizes through quote-based, annual enterprise subscriptions to healthcare organizations, with three primary customer segments: (1) healthcare providers and health systems (e.g., Sutter Health serving 3.5 million patients, Providence, Stanford Medicine, Desert Oasis Healthcare) using the platform in primary care, home health, and specialty settings; (2) Medicare Advantage plans and payers using cognitive screening for population health management, Star Ratings, and HEDIS/CMS compliance; and (3) life and long-term care insurers (e.g., Nationwide, Dai-ichi Life, Hannover Re) for underwriting and policyholder screening. Go-to-market is enterprise field sales targeting large health systems and payers, with deployments measured in weeks. The company holds 11 patents on its assessment technology and reports 375+ peer-reviewed publications, 25 core studies, and SOC 2, HIPAA, and ISO 13485 certifications. Leadership is anchored by co-founder and CEO Elli Kaplan, with a Chief Growth Officer (hired May 2023), CTO, CSO, and VP-level teams in Strategic Partnerships, Marketing, and Customer Success. Total disclosed funding since 2013 is approximately $47M+ across multiple rounds including a $21M raise in 2019 (Khosla Ventures-led) and a $10M raise in November 2022, plus a $3.3M NIA SBIR grant.

Neurotrack firmographics

Firmographics
Name
Neurotrack
Legal name
Neurotrack Technologies, Inc.
Website
https://neurotrack.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Neurotrack is a digital health company that sells an FDA-registered 3-minute cognitive screening test and a Memory Health Program to healthcare providers, Medicare Advantage plans, and long-term care insurers for early detection of Alzheimer's and related dementias.
Ownership category
akta.pro rank

Neurotrack industry classification

Industry
Product category
Digital Cognitive Health Screening
NAICS
Residential Intellectual and Developmental Disability Facilities (623210)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLALACAC
Behavioral Health & Psychiatry Virtual Care (Payer Network)
Healthcare & Life Sciences/Telehealth Platforms/Payer-Sponsored Virtual Care Platforms

Keywords

  • Cognitive screening software
  • Digital health platform
  • Dementia detection tools
  • Clinical assessment software
  • Healthcare screening solutions

Where Neurotrack is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Neurotrack business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Cognitive Assessment Licensing/SaaS: Digital cognitive screening solutions licensed to healthcare organizations including health systems, providers, and payers. The company provides technology that can be administered in-clinic or remotely, with pricing likely based on volume or subscription model.
  2. Health Coaching Services: 1:1 support from board-certified health coaches integrated into the cognitive health program. Partnership with Fortune 100 long-term care insurance provider making services available to policy holders.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise healthcare organizations

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Neurotrack product offering

Product offering

Core offering

Neurotrack develops and sells a 3-minute digital cognitive screening test (FDA-registered Class II medical device) and a Memory Health Program (digital therapeutic with 1:1 health coaching) used by healthcare providers, health systems, payers, and insurers for early detection of mild cognitive impairment and dementia. The platform integrates with all major EHR systems and supports Annual Wellness Visit compliance and population-wide cognitive screening.

Product overview

Neurotrack offers a unified cognitive health platform centered on a 3-minute digital cognitive screening test for clinical detection of mild cognitive impairment and dementia, paired with a Memory Health Program that delivers multi-domain lifestyle interventions and 1:1 health coaching. A patient education library of 100+ articles supports behavior change across modifiable risk factors. The company's original eye-tracking technology, developed by co-founders at Emory University, is now reserved for research applications. All clinical products are FDA-registered, work on any device, integrate with EHR systems, and are SOC 2 and HIPAA compliant.

Differentiator

Problem solved

Functional benefit

Products and services

  • Neurotrack 3-Minute Cognitive Screening Test A rapid digital cognitive screening tool that delivers objective, DSM-5-aligned cognitive baseline assessment in approximately 3 minutes for healthcare providers and payers in primary care and Annual Wellness Visit settings. FDA-registered Class II medical device that integrates with all major EHR systems and works on any device.
  • Neurotrack Memory Health Program An app-based digital therapeutic providing multi-domain lifestyle interventions and 1:1 health coaching to address modifiable Alzheimer's risk factors including physical activity, nutrition, vascular health, sleep, stress, social engagement, and cognitive training. Includes multi-modal neuropsychological assessments for baseline and longitudinal cognitive health measurement; intended for individuals at risk for cognitive decline and their healthcare providers.

Quantifiable outcome

  • 90% of staff say Neurotrack's screener is easy to use
  • +4 more outcomes

Companies that use Neurotrack

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Neurotrack technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Neurotrack partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Sutter HealthcoreStrategic or Co-development Partner · 1 January 2026Sutter Health, serving 3.5 million patients and consistently ranked among top U.S. health systems, is using Neurotrack's cognitive screening for innovative new workflows. This is a flagship partnership demonstrating deployment at a major health system level.
  • NationwidecoreStrategic or Co-development Partner · 1 December 2023Fortune 100 provider of long-term care insurance partnered to make Neurotrack's cognitive assessment and health coaching services available to 30,000+ policy holders. Three-minute online cognitive screening for underwriting.
  • Dai-ichi LifecoreStrategic or Co-development Partner · 1 December 2018Partnership with Japan's second largest life insurance company to sell a dementia insurance product allowing members to take Neurotrack's five-minute Imprint Memory Assessment test via eye-tracking program. Early deployment December 2018.
  • Desert Oasis HealthcarecoreStrategic or Co-development PartnerDesert Oasis Healthcare, a California healthcare provider, implemented Neurotrack's screening program that's closing gaps and connecting patients to care. Features testimonial from Brian Hodgkins, PharmD, EVP of Clinical Operations.
  • University of ArkansascoreStrategic or Co-development PartnerResearch collaboration with Dr. Michelle Gray at the University of Arkansas Exercise Science Research Center for NIA-funded study on health education and coaching reducing Alzheimer's risk factors. Study published in GeroScience.
  • Hannover ReminorChannel Partner/ Reseller/ DistributorMajor reinsurance company partner shown in commercial and research partners section of website.
  • Providence Health SystemcoreStrategic or Co-development PartnerMajor health system partner using Neurotrack's cognitive screening solutions, shown in commercial and research partners section.
  • Alzheimer's Drug Discovery Foundation (ADDF)minorStrategic or Co-development PartnerNon-profit foundation partner shown in commercial and research partners section, focused on accelerating Alzheimer's therapeutics development.
  • Stanford MedicineminorStrategic or Co-development PartnerAcademic medical center partner shown in commercial and research partners section.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Neurotrack competitors and assessment

Company assessment

Direct peers

  • Linus Health: Linus Health is a Boston-based digital health company offering digital cognitive assessments (e.g., DCTclock, Linus Screening) to health systems and payers — the same primary care and MA customer base Neurotrack serves, with overlapping FDA-cleared digital cognitive screening products.
  • Cognivue: Cognivue makes FDA-cleared computerized cognitive assessment devices used in primary care and specialty clinics, overlapping directly with Neurotrack's FDA-registered Class II cognitive screener and the same provider buyer persona.
  • Creyos (formerly Cambridge Brain Sciences): Creyos offers online cognitive assessments and a digital health platform sold to providers, payers, and researchers, competing for the same primary care cognitive screening workflow and population-health use cases as Neurotrack.
  • BrainCheck: BrainCheck provides digital cognitive assessment and care coordination tools used by primary care providers and neurologists. It directly competes with Neurotrack's 3-minute cognitive screener in the same clinical workflow and reimbursement context.

Broad incumbents

  • Biogen: Biogen markets Leqembi, an early-stage Alzheimer's therapeutic whose uptake directly increases demand for early cognitive screening — making it an adjacent incumbent whose commercial priorities shape the market Neurotrack serves.
  • Quest Diagnostics: Quest Diagnostics is a large clinical laboratory network now offering AD-Detect blood-based Alzheimer's tests; as a broad incumbent it competes with Neurotrack at the 'how to detect cognitive decline' clinical workflow level for primary care and payer customers.
  • Signant Health: Signant Health is a large clinical-trial technology provider that historically used Neurotrack-style cognitive assessments (and competes with similar offerings) for CNS trials, representing a broader incumbent in the cognitive assessment ecosystem.

Emerging players

  • Altoida: Altoida develops FDA-cleared digital cognitive assessments using augmented reality and digital biomarkers, with a similar aim of detecting early signs of cognitive decline. It is a more research-stage but directly comparable peer in digital cognitive screening.
  • C2N Diagnostics: C2N Diagnostics provides blood-based biomarker tests (e.g., PrecivityAD) for Alzheimer's detection, representing a complementary rather than overlapping modality that competes for the same 'early Alzheimer's detection' clinical decision point as Neurotrack's screener.
  • Savonix: Savonix offers a digital neurocognitive assessment platform delivered via mobile devices, targeting similar healthcare, payer, and population-health customers as Neurotrack for cognitive screening and brain health monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Neurotrack social profiles

Digital presence

Neurotrack compliance and trust

Trust signal

Compliance3 records

Neurotrack financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurotrack leadership team

Management profile

Number of profiles

Profiles13 records

Neurotrack funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurotrack M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurotrack

What does Neurotrack do?

Neurotrack develops and sells a 3-minute digital cognitive screening test (FDA-registered Class II medical device) and a Memory Health Program (digital therapeutic with 1:1 health coaching) used by healthcare providers, health systems, payers, and insurers for early detection of mild cognitive impairment and dementia. The platform integrates with all major EHR systems and supports Annual Wellness Visit compliance and population-wide cognitive screening.

Is Neurotrack a public or private company?

Neurotrack is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neurotrack founded?

Neurotrack was founded in 2012. It employs 11 to 50 people.

Where is Neurotrack based?

Neurotrack is headquartered in Redwood City, United States, in the North America region.

How does Neurotrack make money?

Two revenue lines are on record. Cognitive Assessment Licensing/SaaS are the primary driver. The others are health Coaching Services.

Who are Neurotrack's main competitors?

Direct peers on record are Linus Health, Cognivue, Creyos (formerly Cambridge Brain Sciences) and BrainCheck. Broad incumbents are Biogen, Quest Diagnostics and Signant Health. Emerging players are Altoida, C2N Diagnostics and Savonix.

Does Neurotrack have an API?

No public API is recorded for Neurotrack.

What industry is Neurotrack in?

Neurotrack's product category is Digital Cognitive Health Screening. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLALAGAC, Neurology Telemedicine Platforms. Its NAICS code is 623210 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
B2B SaaS BlogNeurotrack Revenue 2025: $4.2M Est. ARRNeurotrack offers a digital cognitive screening tool that identifies cognitive impairment in 3 minutes, enabling primary care workflows. The company has raised $57 million and enabled over 170,000 assessments. It was named a winner of the Alzheimer's Association Pitch Competition in February 2023.Nova One AdvisorDigital Brain Health Market Size to Worth Around USD 473.70 Bn by 2035The global digital brain health market is projected to grow from USD 232.59 billion in 2025 to USD 473.70 billion by 2035, at a CAGR of 7.37%, driven by rising neurological disorders, AI integration, and mental health awareness. Recent industry developments include product launches by Neurotrack, FDA breakthrough designation for Cognoa's autism diagnostic AI platform, and clinic openings by Neuroglee Therapeutics. The market faces challenges including data privacy concerns and limited regulatory frameworks for digital mental health tools.American City Business JournalsIn Her Own Words: Elli Kaplan focuses on early dementia detectionElli Kaplan founded Neurotrack to make cognitive testing as routine as checking blood pressure or cholesterol. She hopes other families can benefit from the fruits of this labor.TracxnTop startups in Eye Tracking in United States (Oct, 2025)The article presents a list of top eye-tracking startups in the United States, highlighting companies such as Neurotrack, Rebion, Blink, and Eyefluence. It details their founding years, funding stages, total capital raised, and specific technological applications ranging from clinical diagnostics to wearable displays. The text notes that many founders are alumni of prestigious institutions like MIT and Carnegie Mellon University.GlobeNewswireDigital Neuro Biomarkers Market Research 2025-2030, Competitive Analysis of Altoida, Koneksa, Biogen, Roche, NeuraMetrix, Merck, Linus Health, Neurotrack Technologies, Huma, and NeuraLightThe global digital neuro biomarkers market is projected to reach USD 2.82 billion by 2030, growing at a 25.7% CAGR from 2025 to 2030. Wearable devices held the largest segment share at 39.9% in 2024, and North America led with 37.7% of revenue. Growth is driven by rising neurological disorders and AI integration.PR NewswireMidlife Women's Health Leader Midi Health Partners with Neurotrack to Give Women a Quick and Easy Tool to Help Discern Menopause Brain Fog from More Serious Cognitive ImpairmentMidi Health and Neurotrack announced a partnership to offer a 3-minute online cognitive screening for women experiencing menopause brain fog. The test helps distinguish temporary menopause-related symptoms from more serious cognitive impairment, with low scores referred to providers. Midi reports 74% of patients experience brain fog.NationwideThree-minute online cognitive screening simplifies long-term care underwritingNationwide introduced a three-minute online cognitive screening for its CareMatters long-term care products, replacing the traditional 20-minute telephone assessment. The assessment uses Neurotrack's technology and is available today with select relationships, rolling out more broadly in Q2 2024.ForbesThis Entrepreneur Aims To Make Cognitive Screening As Easy As Checking Your PulseNeurotrack raised $10 million in funding to accelerate its 3-minute cognitive screening test, bringing total funding to about $57 million. The test screens for processing speed and executive function, aiming to integrate into wellness visits. The company plans to scale commercialization and develop a digital therapeutic for mild cognitive impairments.PR NewswireNeurotrack Expands C-suite with New Chief Growth Officer to Accelerate Partnerships in Health System and Provider MarketsNeurotrack, a Redwood City, California-based digital health company specializing in cognitive health assessments, announced the appointment of Shawn Lemerise as its first Chief Growth Officer. Lemerise brings over 20 years of healthcare experience, particularly in health system and provider markets, and will focus on driving sales, marketing strategy, and product innovation in the newly created role. The hire comes amid growing demand for cognitive screening solutions driven by an aging population, undiagnosed Alzheimer's prevalence, and new CMS reimbursement codes for annual cognitive assessments.